information from Dr. Amita Gupta , MD , Johns Hopkins Bloomberg School of
Death in the early months following initiation of
antiretroviral treatment is common among patients with advanced HIV living in
resource-limited countries with a high prevalence of HIV.
Despite the success of antiretroviral programs in these
resource-limited areas, many patients still present for treatment with advanced
HIV disease and up to 17% of adults die in the first year of antiviral therapy,
the researchers wrote.
"One of the biggest drivers of morbidity and
mortality in this setting is tuberculosis,"
He noted that up to 70% of
patients with tuberculosis living in sub-Saharan Africa are HIV positive. "Patients with HIV may not have commonly recognized symptoms of tuberculosis, which complicates diagnosis," he said.